Download presentation
Presentation is loading. Please wait.
1
Novel Therapeutics in MS
3
Role of T Cells in MS
4
Role of B Cells in MS
5
Role of T Cells and B Cells in Disease Progression
6
T-Cell and B-Cell Targeted Therapies
7
T-Cell and B-Cell Targeted Therapies (cont)
8
Natalizumab: MOA
9
Natalizumab: Clinical Outcomes
10
Altering the Immune Function of T Cells and B Cells
11
Fingolimod: MOA
12
Fingolimod: Clinical Outcomes
13
Alemtuzumab: MOA
14
Alemtuzumab: Clinical Outcomes
15
Cladribine: MOA
16
Cladribine: Clinical Outcomes
17
Daclizumab: MOA
18
Daclizumab: Clinical Outcomes
19
Investigational T-Cell Targeting Therapies: Siponimod
20
S1PR Modulators
21
Investigational T-Cell Targeting Therapies: Other
22
B-Cell Ontogeny
23
Ocrelizumab: ORATORIO Study in PPMS
24
Immune-Depleting Strategies
25
Investigational B-Cell Targeted Therapies: Ofatumumab
26
Investigational B-Cell Targeted Therapies: Ofatumumab (cont)
27
Investigational B-Cell Targeted Therapies: Ublituximab and Inebilizumab
28
Looking to the Future
29
Conclusions
30
Abbreviations
31
Abbreviations (cont)
32
Abbreviations (cont)
33
Abbreviations (cont)
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.